Copaxone Generics: FDA Approval Standards Defy Teva’s Argument On Complexity
Sandoz/Momenta’s Glatopa (glatiramer) met four criteria for equivalence that ‘provide overlapping and confirmatory evidence of active ingredient sameness,’ FDA says.
You may also be interested in...
House and Senate letters ask why Mylan's autoinjector doesn't have competition, offering a preview of potential debates on renewal of the generic user fee program.
Agency's latest report to Congress highlights resource burden, implies legislative fix may better discourage frivolous petitions.
FDA’s approval of the first ANDA for an MS therapy signals the agency’s determination to find a way to get generic versions of complex drugs to market. What if any lessons does that hold for biosimilars?